The global healthcare landscape is undergoing a profound transformation with the emergence of virtual hospitals, a paradigm ...

Geneva, Switzerland – September 19, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental disorders, announced ...

Presentations Will Highlight Oral Prolonged-Release Ketamine (KET01) And its Minimal Impact on Sleep, Alongside Excellent Day-One Tolerability in PatientsMUNICH, Sept. 18, 2024 (GLOBE NEWSWIRE) -- ...

The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for Biomedical Artificial Intelligence (AI) based on a € 150 million funding from the ...

Gedeon Richter UK Ltd. (“Gedeon Richter”) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has extended the licence for Benilexa One Handed from 6 to 8 years as a ...

Biognosys’ Spectronaut®, the leading vendor-agnostic software for DIA proteomics, is now directly available from Thermo Fisher Scientific under a reselling agreementEnd users can get access to Thermo ...

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Matthias Will, M.D., as Chief ...

Aston Institute for Membrane Excellence held its official academic launch event on 13 SeptemberMore than 100 biologists, chemists, physicists and engineers gathered at Aston University to learn about ...

Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce ...

Amsterdam, Netherlands) A pioneering study, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in ...

ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReadyTM, today announced that ImmunoScape (a Singapore-U.S. based TCR-T therapy company) ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...